Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
bluebird bio Inc
BLUE | US
0.50
USD0.01
1.22%
BLUE | US
About bluebird bio Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
0.50
Open
0.49
High
0.50
Low
0.48
bluebird bio Inc. a biotechnology company researches develops and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205 HGB-206 and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204 HGB-205 HGB-207 and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals Inc. and changed its name to bluebird bio Inc. in September 2010. bluebird bio Inc. was incorporated in 1992 and is headquartered in Somerville Massachusetts.
View LessBLUE | US
Risk
89.2
Sharpe
-0.75
Luna's Score
42/100
Recommendation
Sell
Luna says (BLUE | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
57.5%1 month
89.2%3 months
100.7%6 months
91.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.78
Debt to equity
7.37
Debt to assets
0.72
Ent. to EBITDA
-1.50
Ent. to rev.
6.21
PEG
0.32
Other Fundamentals
EBITDA
-302.11M
MarketCap
96.34M
MarketCap(USD)
96.34M
Div. yield
-
Op. margin
-548.99
Erngs. growth
-
Rev. growth
133.70
Ret. on equity
-186.70
Short ratio
6.46
Short perc.
27.38
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.10
Range1M
0.12
Range3M
0.80
Volumes: Market Activity
Rel. volume
0.51
Price X volume
1.55M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.50 | 0.53 | Cheaper |
| Ent. to Revenue | 6.21 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.78 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 100.74 | 72.80 | Riskier |
| Debt to Equity | 7.37 | -1.23 | Expensive |
| Debt to Assets | 0.72 | 0.25 | Expensive |
| Market Cap | 96.34M | 3.66B | Emerging |
